Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
9 drugs in development
By Therapeutic Area
top 3
R&D Momentum
66/100
Pipeline Velocity
25/100
Trial Completion Rate
82/100
Pipeline Concentration
42/100
Pipeline Freshness
5/100
Strategic Signals
Activity
Last 14 days
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)
Regional Cerebral Blood Flow Studies of Object Perception, Identification, Localization, and Memory
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
Top-Down Attentional Control of Visual-Processing
PET Imaging of Noradrenergic Transmission in the Brain
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
Bipolar Genetics: A Collaborative Study
An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Inpatient Evaluation of Neuropsychiatric Patients
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)